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The study was conducted at the University of Veterinary Medicine in Cluj-Napoca (Romania) in the animal 
physiology department, between May 2018 and June 2019. The aim of the study was to assess the influence 
of a probiotic product with Bacillus subtilis and Pediococcus acidilactici on healthy dogs. The probiotic was 
administered orally once a day to six healthy adult dogs from 1 year to 7 years old for a period of 30 days. 
The dogs entering the study were submitted to a general clinical examination. At day 1 and day 31/36 of the 
study, blood samples was collected and haematological parameters were evaluated. The objectives of the 
research were multiple. First of all, we observed whether the probiotic influenced the general health of the 
dogs and changes in clinical parameters. Then, the dynamics of the haematological parameters was 
identified. The in vivo study showed the safety of the probiotic product on healthy dogs and the minimal 
impact on hematologic parameters. In fact, no adverse reactions were observed. 
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Introduction 
The use of probiotics in human has been reported hundred years ago (Endres et al., 2009). 
They have worldwide utilization and are widely developed in Asia. As an example, the Japanese 
fermented soybean dish Natto is famous for its probiotic’s properties. Many more natural dishes 
associated with probiotics are found across the world such as TapaiUbi (Malaysia), Douchi 
(China), Rabadi (India, Pakistan), Soibum (India), etc... (Elseghabee et al., 2017) 
These last decades’ probiotics have been described in many ways by a large panel of 
scientists. In 2014, experts have established a common opinion about probiotics (Bernadeau et al., 
2017). Probiotics are usually described as live microorganisms (bacteria or yeast usually) that 
confer a health benefit on the host when they are consumed in adequate quantity. Probiotics can be 
integrated in various types of products such as feed/food, therapeutic drugs or feed supplements 
(Amraii et al., 2014). 
Probiotics must fulfil some safety criteria to be used in animals and human health. They 
should be non-toxic, non-pathogenic and be a normal inhabitant of the gastrointestinal tract (GIT) 
host. Accurate taxonomic identification is required to avoid the use of unsafe bacteria (Gaggia et 
al., 2010). 
Other criteria such as antagonism towards pathogenic bacteria and be genetically stable to 
avoid antibiotic resistance or other adverse effects. They should show stability during processing, 
storage and delivery (Gaggia et al., 2010). More assays must be performed to confirm the safety of 
probiotics such as antibiotic resistance, hemolytic activity, and production of enzymes, toxins or 
biogenic amines (Gaggia et al., 2010). 
Probiotics related to Bacillus species emerged 15 years ago. Bacillus subtilis, Bacillus 
clausii, Bacillus cereus, Bacillus coagulans, Bacillus licheniformis, Bacillus indicus are the 





The objectives of the research were multiple. The dynamics of the haematological 
parameters in healthy dogs treated with probiotics was identified. In addition the influence on the 
general health of the dogs was analysed and changes in clinical parameters were observed. 
 
Material and methods 
The study was conducted between May 2018 and June 2019 at the University of Veterinary 
Medicine in Cluj-Napoca (Romania). The investigations were performed in three departments of 
the university: Animal physiology, Animal Nutrition and Internal medicine. 
Study design 
A total of 6 adults dogs aged between 1year and 7 years old entered in the study from 10th 
of April till the 29th of July. The probiotic product composed of Bacillus subtilis and Pediococcus 
acidilactici was given to the 6 dogs once a day with the meal during a thirty day period. 
In day 0 dogs were clinical examined and biological samples were collected (blood) for 
para-clinical examinations. Between day 1 and day 30 the probiotic product was administrated to 
the animals, respecting the manufacturer recommendations. In day 31, all the dogs were clinical 
examined and biological samples were collected (blood) for the para-clinical examinations. 
All the clinical examinations for the animals have the aim to diagnose the general health 
status and the temperature, cardiac frequency and respiratory frequency registration. 
Study population 
Inclusion criteria for the healthy dogs (table 2.1) were: absence of gastro-enterological 
manifestations (diarrhea, vomiting), no antibiotic treatment in the last 6 months, clinically healthy, 
one meal/day. Exclusion criteria for this category of dogs were: gastro-enterological manifestations 
(diarrhea, vomiting), antibiotic treatment in the last 6 months. 
 
Table 2.1. – Patient description and code 
Patient 
code Breed Age Sex Observations 






no specific external or 
internal treatment 
P-02 Swiss White Shepherd 3 years castrated male 
P-03 Border collie 3 years female 
P-04 Shetland shepherd 1 year female 
P-05 Shetland shepherd 7 years female 
P-06 Mixed dog breed 1.8-year female 
 
Treatment 
The probiotic product tested is composed of two strains of bacteria: Bacillus subtilis HU58 
and Pediococcus acidilactici. The probiotic product is presented as capsules. During thirty days 
one capsule per day was administered to each dog with the meal. Moreover, an addition of liver 
powder is used to improve the taste of the probiotic product and facilitates its taking. 
Clinical investigations 
To ensure that the dogs entering the study are healthy and for observed the evolution of the 
principals functions we performed individual clinical investigations. A general clinical 
examination was performed and some clinical parameters (temperature, cardiac frequency, 
respiratory rate) were measured in all six dogs. For these investigations we based the normal range 






The blood will be collected in hematologic tubes with an anticoagulant (EDTA). The 
hematologic samples are analyzed via the device ABACUS JUNIOR VET®. These evaluations 
were performed ante- (day 0) and post-administration (day 31) of the probiotic (table 2.2). 
 
Table 2.2- Hematologic parameters and their methods 
No. Parameter The method 
1. Hematocrit (HCT) Calculated from RBC and MCV, HCT= RBC x MCV x 100 
 
2. Hemoglobin (HGB) Measured photometrically  
3. Red blood cell count (RBC) Number of erythrocytes Average volume of individual 
4. Mean corpuscular volume (MCV) erythrocytes derived from the RBC histogram 
 
5. Mean corpuscular hemoglobin (MCH) MCH= HGB/RBC  
6. Mean corpuscular hemoglobin concentration (MCHC) MCHC= [HGB / HCT] x 100 
 
7. Total White blood cell count (WBC) Number of leucocytes  




Data were analyzed using a condition (healty dogs) × experiment time (pre administration 
and 31-day post-administration) analysis of variance (ANOVA). Significance was set at P < 0.05. 
The significance of results was determined using Student-Newman-Keuls Multiple Comparisons 
Test. 
 
Results and discussion 
Clinical investigations 
A general clinical examination is performed on all the dogs before to start the probiotic 
treatment and to the end of the study. 
All the dogs presented no significant modifications at general examination. The 
temperature for all the dogs was normal between 37.9-39.9 °C. The cardiac frequency was without 
significant importance. All the dogs present a higher value for the respiratory rate between. The 
normal value at rest for the respiratory frequency is between 18 -34 breaths per minute. The fact 
that all the dogs had an increased in respiratory rate was not alarming it could be due to the 
excitement, stress and/or the too high temperature in the room. 
The clinical appearance of healthy dogs was not altered by the treatment. No symptoms 
such as diarrhea or vomiting have been observed. In dog P-03, hair loss and skin lesions at level of 
the left anterior limb were observed. Problems started during gestation and were maintained after 
parturition (3 months ago). Probiotic treatment improved the appearance of the hair and induced 
skin lesions improvement. 
Hematological parameters 
The following table (table 3.1) represents the hematological results before and after the 





Table 3.1 - Results for hematological parameters before and after probiotics treatment 
Hematologic 
Parameters P 01 P 02 P 03 P 04 P 05 P 06 
Day 0 31 0 31 0 31 0 31 0 31 0 31 
HCT 
(37-55%) 46.74 47.01 43.91 39.07 48.00 48.08 42.76 48.94 47.67 47.53 45.25 42.71 
HGB 





























(60-77 fL) 66.00 66.00 66.00 63.00 70.00 66.00 73.00 73.00 68.00 69.00 63.00 62.00 
MCH 
(19.5-24.5 pg) 30.00 30.50 29.50 30.70 30.00 30.20 31.20 35.00 29.90 31.20 29.60 31.70 
MCHC 
(32-36 g/dL) 45.60 46.20 45.00 49.10 42.90 45.80 42.50 48.20 44.20 45.00 47.20 50.80 
WBC 
(6-17*109/L) 13.35 12.95 12.13 15.22 16.29 12.43 11.43 17.28 9.75 16.99 18.80 19.69 
PCT 
(%) 0.11 0.21 0.15 0.18 0.15 0.33 0.37 0.45 0.51 0.37 0.25 0.30 
 
The results show for P-01, P-03, P-04 an increase of the hematocrit. For P-02, P-05 and P- 
06 there is a decrease in hematocrit. However, the differences are not significative. For all the dogs 
except P-02 we observe a slight increase in hemoglobin production after the treatment. We observe 
a slight increase of the red blood cells for P-01, P-03, P-04 but a slight decrease for P-02, P-05 and 
P-06. However, the differences are not significative. 
The MCV presents no variation in P-01 and P-04 while we observe a decrease in MCV 
after probiotics treatment for P-02, P-03 and P-06; P-05 presents an increase of the MCV after the 
probiotic’s treatment. For all dogs we observe an increase of the MCH and the MCHC after the 
probiotic’s treatment. These parameters are in the normal range of value and their variations are 
not significant. 
We observe for P-01 and P-03 a decrease of the white blood cells while for P-02, P-04, P- 
05 and P-06 there is an increase in white blood cells. 
All the dogs except P-05 show an increase in platelets after the probiotic’s treatment. Even 
if some of the results show values outside of the normal range it is not alarming because it can be 
due to the device. The hematological results are considered in the normal range for dogs and don’t 
represent any signs of diseases. 
The hematological parameters for our six dogs are quite heterogenous but are always in 
the normal range of values for dogs. Nevertheless, we observe a slight increase in hemoglobin 
(Hb), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration 
(MCHC), plateletcrit (PCT) and white blood cells (WBC) for almost all the dogs after the probiotic 
treatment. 
These results are not significant and confirm the study of Hong et al. (2008). In fact, in 
their study, they tested the effect of oral administration of Bacillus subtilis for 30 days in rabbit. 
After the probiotic treatment, rabbits don’t show any significant changes in hematological 
parameters (Hong et al., 2008). 
The ability of Bacillus subtilis to form biofilms, to sporulate anaerobically, to secrete 
antimicrobials and the adaptation to gastrointestinal tract made authors like Hong et al. (2009) to 





The table 3.2 records the percentage of leucocytes before and after the probiotic’s treatment 
for all the six cases. 
 
Table 3.2 - Percentage of leucocytes before and after the probiotic’s treatment 
Leucocytes P 01 P 02 P 03 P 04 P 05 P 06 
Day 0 31 0 31 0 36 0 36 0 36 0 31 
Neutrophil 
(58-85%) 43 51 63 40 47 65 62 56 61 57 54 59 
Eosinophil 
(0-9%) 7 7 6 30 5 6 8 5 4 6 6 7 
Basophil 
(0-1%) 0 0 0 0 0 0 0 1 0 0 0 0 
Monocyte 
(2-10%) 17 12 18 13 20 12 10 18 18 16 9 11 
Lymphocyte 
(8-21%) 33 30 13 17 28 17 20 20 17 21 31 23 
 
For P-01, P-03 and P-06 there is an increase of the neutrophils. For P-02, P-04 and P-05 
there is a decrease in neutrophils. 
P-02 presents an important increase of the eosinophils from 6 to 30% after probiotics treatment. P- 
03, P-05 and P-06 show a slight increase in eosinophils. While P-04 presents a slight decrease in 
eosinophils. 
Concerning P-02, the important increase in eosinophils can correlates with the second 
coprological examination confirming the presence of intestinal parasites. Even if the mechanism is 
not very clear, the probiotics influence and modifies the gastrointestinal environment. The process 
involves a stimulation of immune system cells to produce cytokines, which play a role in the 
induction and regulation of the immune response. The environment became less adequate for 
parasites and a possible release of toxins by dead parasites is a valuable hypothesis. Eosinophils 
increase in the presence of parasitic toxins and in allergic reactions (Travers et al., 2011). 
Usually in dogs, basophils are very rare and that why there are not present in our results. 
We found one basophil in P-04 after probiotics treatment. However, it is not significative. 
For P-01, P-02, P-03 and P-05 there is a decrease of the monocytes while for P-04and P-06 there 
is an increase in monocytes. 
We observe for P-01, P-03 and P-06 a decrease of lymphocytes. For P-02 and P-05 there 
is an increase in lymphocytes; P-04 show no variation in lymphocytes. 
Even if the monocytes and lymphocytes seem a bit elevated, it is not alarming. The 
leucocytes values before and after probiotic treatment present heterogenous results but are in the 
normal range of values for dogs. The eosinophils tend to slightly increase in most of the dogs after 
treatment. Neutrophils, basophils, monocytes and lymphocytes increase or decrease according to 
the individual. These results confirm the study of Hong et al. (2008) and conduct to no significant 
changes of the leucocytes after probiotic treatment. 
 
Conclusions 
The clinical appearance of dogs is not altered by the treatment however one of the dogs 






The hematological and biochemical parameters have shown slight changes pre and post 
administration of probiotics with values in the normal range. 
The use of the probiotic with Bacillus subtilis and Pediococcus acidilactici presented no 
adverse effects in healthy dogs. 
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